CLEC18A

Across TCGA pan-cancer cohorts, CLEC18A RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of CLEC18A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CLEC18A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CLEC18A is over-expressed in tumor, although a few such as KICH and KIRP show the opposite, repressed pattern.

KIRC, HNSC, and KICH are the cancer types where CLEC18A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLEC18A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+2.437	<.001	11	view →
HNSC	Male	IV	+0.042	<.001	8	view →
KICH	All	II,III,IV	−0.835	<.001	7	view →
LIHC	Male	All	+0.028	<.001	7	view →
KIRP	Male	All	−1.066	<.001	6	view →
BLCA	All	All	+0.082	.006	6	view →
STAD	All	All	+0.079	.001	6	view →
CHOL	Male	All	+0.143	.026	2	view →
BRCA	All	IV	+0.095	.013	2	view →
COAD	Female	IV	+0.315	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

CLEC18A–KIRC

Open the KIRC breakdown →